A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity.

A new method for predicting signal sequence cleavage sites

von HEIJNE, G. (1986) · Nucleic Acids Research · doi:10.1093/nar/14.11.4683 · Cited by 4,473

Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA

Pelletier, J., & Sonenberg, N. (1988) · Nature · doi:10.1038/334320a0 · Cited by 1,953

Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.

Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotný, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., & Crea, R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.5879 · Cited by 1,610

pEF-BOS, a powerful mammalian expression vector

Mizushima, S., & Nagata, S. (1990) · Nucleic Acids Research · doi:10.1093/nar/18.17.5322 · Cited by 1,594

Single-Chain Antigen-Binding Proteins

Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S., Lee, T. T., Pope, S. H., Riordan, G. S., & Whitlow, M. D. (1988) · Science · doi:10.1126/science.3140379 · Cited by 1,522

"Diabodies": small bivalent and bispecific antibody fragments.

Holliger, P., Prospero, T. D., & Winter, G. P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6444 · Cited by 882

Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.

Yokota, T., Milenic, D. E., Whitlow, M. D., & Schlom, J. (1992) · PubMed · Cited by 819

Cloning immunoglobulin variable domains for expression by the polymerase chain reaction.

Orlandi, R., Güssow, D., Jones, P. T., & Winter, G. P. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.10.3833 · Cited by 715

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma

Riethmüller, G., Gruber, R., Schneider-Gädicke, E., Schlimok, G., Witte, J., Raab, R., Pichlmayr, R., Pichlmaier, H., Schmiegel, W., Buggisch, P., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92398-1 · Cited by 633

Hybrid antibodies can target sites for attack by T cells

Staerz, U. D., Kanagawa, O., & Bevan, M. J. (1985) · Nature · doi:10.1038/314628a0 · Cited by 492

Immunotherapy in Hematological Malignancies: Recent Advances and Open Questions

Tawfik, E. A., Aldrak, N. A., Albrahim, S. H., Alzahrani, D. A., Alfassam, H. A., Alkoblan, S. M., Almalik, A., Chen, K., Abou-Khalil, R., Shah, K., et al. (2021) · Immunotherapy · doi:10.2217/imt-2021-0065 · Cited by 18

Monoclonal antibody biosimilars for cancer treatment

Broer, L. N., Knapen, D. G., de Groot, D. J. A., Mol, P. G. M., Kosterink, J. G. W., de Vries, E. G. E., & Hooge, M. N. L. (2024) · iScience · doi:10.1016/j.isci.2024.110115 · Cited by 16

Innovative gene engineering strategies to address tumor antigen escape in cell therapy

Chen, Y., Niu, S., Li, Y.-R., & Yang, L. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07259-8 · Cited by 19

Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer

Park, S., Ho, C. E., Darnell, E. P., Wolff, A. N., Takei, H., Birocchi, F., Bouffard, A. A., Salas‐Benito, D., Escobar, G., Leick, M. B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66102-2 · Cited by 16

Bispecific T cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection

Pendzialek, J., Roose, K., Smet, A., Schepens, B., Kufer, P., Raum, T., Baeuerle, P. A., Muenz, M., Saelens, X., & Fiers, W. C. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.02.016 · Cited by 17

A semi high-throughput method for screening small bispecific antibodies with high cytotoxicity

Sugiyama, A., Umetsu, M., Nakazawa, H., Niide, T., Onodera, T., Hosokawa, K., Hattori, S., Asano, R., & Kumagai, I. (2017) · Scientific Reports · doi:10.1038/s41598-017-03101-4 · Cited by 15

Exogenously added GPI-anchored tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) displays enhanced and novel biological activities

Djafarzadeh, R., Mojaat, A., Vicente, A. B., von Lüttichau, I., & Nelson, P. J. (2004) · Biological Chemistry · doi:10.1515/bc.2004.081 · Cited by 16

PSMA-targeted bispecific Fab conjugates that engage T cells

Patterson, J. T., Isaacson, J., Kerwin, L., Atassi, G., Duggal, R., Bresson, D., Zhu, T., Zhou, H., Fu, Y., & Kaufmann, G. F. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.09.065 · Cited by 16

Structure and function of therapeutic antibodies approved by the US FDA in 2024

Strohl, W. R. (2025) · Antibody Therapeutics · doi:10.1093/abt/tbaf014 · Cited by 16

Bi-Specific Antibodies in Cancer Therapy

Wang, H., Liu, Y., Wei, L., & Guo, Y. (2002) · Advances in experimental medicine and biology · doi:10.1007/0-306-46817-4_32 · Cited by 15

Construction, Expression, and Characterization of a Recombinant Immunotoxin Targeting EpCAM

Lv, M., Qiu, F., Li, T., Sun, Y., Zhang, C., Zhu, P., Qi, X., Wan, J., Yang, K., & Zhang, K. (2015) · Mediators of Inflammation · doi:10.1155/2015/460264 · Cited by 15

Recombinant GPI-Anchored TIMP-1 Stimulates Growth and Migration of Peritoneal Mesothelial Cells

Djafarzadeh, R., Sauter, M., Notohamiprodjo, S., Noeßner, E., Goyal, P., Siess, W., Wörnle, M., Ribeiro, A., Himmelein, S., Sitter, T., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033963 · Cited by 14

Advances in Bispecific Antibodies Engineering: Novel Concepts for Immunotherapies

Spasevska, I. (2015) · Journal of Blood Disorders & Transfusion · doi:10.4172/2155-9864.1000243 · Cited by 13

General In Vitro Method to Analyze the Interactions of Synthetic Polymers with Human Antibody Repertoires

Soshee, A., Zürcher, S., Spencer, N. D., Halperin, A., & Nizak, C. (2013) · Biomacromolecules · doi:10.1021/bm401360y · Cited by 17

Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab

Ku, M., Chong, G., & Hawkes, E. A. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.08.001 · Cited by 14

Impact of enzymatic reduction on bivalent bispecific antibody fragmentation and loss of product purity upon reoxidation

Swope, N. K., Chung, W. K., Cao, M., Motabar, D., Liu, D., Ahuja, S., & Handlogten, M. W. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27264 · Cited by 14

Rapid Detection of Hepatitis B Virus Surface Antigen by an Agglutination Assay Mediated by a Bispecific Diabody against Both Human Erythrocytes and Hepatitis B Virus Surface Antigen

Chen, Y., Qiao, Y., Zhao, X., Chen, H., Wang, Y., & Wang, Z. (2007) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00310-06 · Cited by 14

TuPPL: Tub-tag mediated C-terminal protein–protein-ligation using complementary click-chemistry handles

Stengl, A., Gerlach, M., Kasper, M., Hackenberger, C. P. R., Leonhardt, H., Schumacher, D., & Helma, J. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c9ob00508k · Cited by 14

Recombinant TIMP-1-GPI inhibits growth of fibrosarcoma and enhances tumor sensitivity to doxorubicin

Bao, Q., Niess, H., Djafarzadeh, R., Zhao, Y., Schwarz, B., Angele, M. K., Jauch, K. W., Nelson, P. J., & Bruns, C. J. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0294-5 · Cited by 14

The evolving role of catumaxomab in gastric cancer

Lordick, F., Ott, K., Weitz, J., & Jäger, D. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.9.1407 · Cited by 14

Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscapePreprint

Cook, A. L., Sur, S., Dobbyn, L., Watson, E., Cohen, J. D., Ptak, B., Lee, B. S., Paul, S., Hsiue, E. H.-C., Popoli, M., et al. (2024) · eLife · doi:10.7554/elife.95952 · Cited by 16

An engineered ultra‐high affinity Fab‐Protein G pair enables a modular antibody platform with multifunctional capability

Ślężak, T., Bailey, L. J., Jaskółowski, M., Nahotko, D. A., Filippova, E. V., Davydova, E. K., & Kossiakoff, A. A. (2019) · Protein Science · doi:10.1002/pro.3751 · Cited by 12

T-cell Activating Tribodies as a Novel Approach for Efficient Killing of ErbB2-positive Cancer Cells

Riccio, G., Ricardo, A. R., Passariello, M., Saraiva, K., Rubino, V., Cunnah, P., Mertens, N., & Lorenzo, C. D. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000248 · Cited by 13

Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology

Suzuki, M., Curran, K. J., & Cheung, N. V. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25513 · Cited by 13

Productivity and Quality of Recombinant Proteins Produced by Stable CHO Cell Clones can be Predicted by Transient Expression in HEK Cells

Diepenbruck, C., Klinger, M., Urbig, T., Baeuerle, P. A., & Neef, R. (2012) · Molecular Biotechnology · doi:10.1007/s12033-012-9590-z · Cited by 13

Engineering and Characterization of a Novel Fusion Protein Incorporating B7.2 and an Anti–ErbB-2 Single-Chain Antibody Fragment for the Activation of Jurkat T Cells

Marshall, K. W., & Marks, J. D. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200101000-00004 · Cited by 13

Targeting Prostate Cancer Using Bispecific T-Cell Engagers against Prostate-Specific Membrane Antigen

Das, G., Ptáček, J., Havlínová, B., Nedvědová, J., Bařinka, C., & Nováková, Z. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00159 · Cited by 13

An engineered genetic selection for ternary protein complexes inspired by a natural three-component hitchhiker mechanism

Lee, H., Portnoff, A. D., Rocco, M. A., & DeLisa, M. P. (2014) · Scientific Reports · doi:10.1038/srep07570 · Cited by 12

Generation of GPI-linked CCL5 based chemokine receptor antagonists for the suppression of acute vascular damage during allograft transplantation

Notohamiprodjo, M., Djafarzadeh, R., Mojaat, A., von Lüttichau, I., Gröne, H., & Nelson, P. J. (2005) · Protein Engineering Design and Selection · doi:10.1093/protein/gzi072 · Cited by 12

Development of a bispecific immune engager using a recombinant malaria protein

Nordmaj, M. A., Roberts, M. E., Sachse, E. S., Dagil, R., Andersen, A. P., Skeltved, N., Grunddal, K. V., Erdoğan, S. M., Choudhary, S., Gustsavsson, T., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03611-0 · Cited by 11

In vitro and in vivo properties of a dimeric bispecific single‐chain antibody IgG‐fusion protein for depletion of CCR2+ target cells in mice

Schneider, M. A., Brühl, H., Wechselberger, A., Cihak, J., Stangassinger, M., Schlöndorff, D., & Mack, M. (2005) · European Journal of Immunology · doi:10.1002/eji.200425512 · Cited by 12

Monoclonal antibody treatment of colorectal cancer

Pullyblank, A. M., & Monson, J. R. T. (1997) · British journal of surgery · doi:10.1002/bjs.1800841106 · Cited by 12

Bispecific antibodies in acute lymphoblastic leukemia therapy

Chitadze, G., Laqua, A., Lettau, M., Baldus, C. D., & Brüggemann, M. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1831380 · Cited by 11

Neurologic Complications of Cancer Immunotherapy

Alsalem, A., Scarffe, L. A., Briemberg, H., Aaroe, A., & Harrison, R. A. (2023) · Current Oncology · doi:10.3390/curroncol30060440 · Cited by 12

TIMP-1-GPI in combination with hyperthermic treatment of melanoma increases sensitivity to FAS-mediated apoptosis

Djafarzadeh, R., Milani, V., Rieth, N., von Luettichau, I., Skrablin, P. S. A., Hofstetter, M., Noeßner, E., & Nelson, P. J. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0559-5 · Cited by 11

A novel recombinant bispecific single-chain antibody, bscWue-1 × CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells

Hönemann, D., Kufer, P., Rimpler, M., Chatterjee, M., Friedl, S., Riecher, F., Bommert, K., Dörken, B., & Bargou, R. C. (2004) · Leukemia · doi:10.1038/sj.leu.2403264 · Cited by 11

Imm TAC /Anti‐ PD ‐1 antibody combination to enhance killing of cancer cells by reversing regulatory T‐cell‐mediated immunosuppression

Zhang, H., Li, Y., Liu, X., Liang, Z., Yan, M., Liu, Q., Chen, A., Bao, Y., Zhou, C., Li, S., et al. (2018) · Immunology · doi:10.1111/imm.12954 · Cited by 11

Engineering Platforms for T Cell Modulation

Hickey, J. W., Kosmides, A. K., & Schneck, J. P. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.06.003 · Cited by 11

A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells

Aschmoneit, N., Steinlein, S., Kühl, L., Seifert, O., & Kontermann, R. E. (2021) · Scientific Reports · doi:10.1038/s41598-021-93351-0 · Cited by 11

Comparison of strategies for the construction of libraries of artificial antibodies

Iba, Y., & Kurosawa, Y. (1997) · Immunology and Cell Biology · doi:10.1038/icb.1997.33 · Cited by 11

Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline

Shastri, T., Trabolsi, A., Arumov, A., & Schatz, J. H. (2025) · BioDrugs · doi:10.1007/s40259-025-00735-z · Cited by 12

The preparation of VEGFR1/CD3 bispecific antibody and its specific cytotoxicity against VEGFR1‐positive breast cancer cells

Tang, P., Li, L., Zhou, Y. N., Shen, C., Kang, Y., Yao, Y., Cheng, Y., Gou, L., & Yang, J. (2013) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1187 · Cited by 10

Computational Biochemistry of Antibodies and T-Cell Receptors

Novotný, J., & Bajorath, J. (1996) · Advances in protein chemistry · doi:10.1016/s0065-3233(08)60490-8 · Cited by 10

Minimal Residual Disease: Detection, Clinical Relevance, and Treatment Strategies

Dwenger, A., Lindemann, A., & Mertelsmann, R. H. (1996) · Journal of Hematotherapy · doi:10.1089/scd.1.1996.5.537 · Cited by 10

Preferential Targeting of CD4-CCR5 Complexes with Bifunctional Inhibitors: A Novel Approach to Block HIV-1 Infection

Mack, M., Pfirstinger, J., Haas, J., Nelson, P. J., Kufer, P., Riethmüller, G., & Schlöndorff, D. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.11.7586 · Cited by 10

Monoclonal antibodies in cancer therapy

Gruben, R., Holz, E., & Riethm�ller, G. (1996) · Springer Seminars in Immunopathology · doi:10.1007/bf00820669 · Cited by 10

B-cell lymphoma: Advances in pathogenesis, diagnosis, and targeted therapies

Patil, S., Rajput, S., Patil, S., & Mhaiskar, A. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156036 · Cited by 12

The Role of NOTCH1, GATA3, and c-MYC in T Cell Non-Hodgkin Lymphomas

Al‐Khreisat, M. J., Hussain, F. A., Abdelfattah, A., Almotiri, A., Al-Sanabra, O. M., & Johan, M. F. (2022) · Cancers · doi:10.3390/cancers14112799 · Cited by 9

Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment

Füchsl, F., & Krackhardt, A. M. (2022) · Cancers · doi:10.3390/cancers14174192 · Cited by 9

Potential niche indications for blinatumomab as a bridge to hematopoietic cell transplantation

Zeng, Y., & Katsanis, E. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.186 · Cited by 9

Modulation of Plant Function and Plant Pathogens by Antibody Expression

Fischer, R., Drossard, J., Schillberg, S., Artsaenko, O., Emans, N., & Nähring, J. M. (2000) · Springer eBooks · doi:10.1007/978-94-015-9423-3_5 · Cited by 9

Direct Antigen Capture by Soluble scFv Antibodies

Kala, M., Bajaj, K., & Sinha, S. (2001) · Applied Biochemistry and Biotechnology · doi:10.1385/abab:90:1:11 · Cited by 9

Current treatment strategy and new agents in mantle cell lymphoma

Ogura, M. (2010) · International Journal of Hematology · doi:10.1007/s12185-010-0607-8 · Cited by 8

Solid-Phase Bioconjugation of Heterobifunctional Adaptors for Versatile Assembly of Bispecific Targeting Ligands

Liu, H. Y., Zrazhevskiy, P., & Gao, X. (2014) · Bioconjugate Chemistry · doi:10.1021/bc5002455 · Cited by 8

Serum signaling factors and spheroids

Chun, M. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00079-2 · Cited by 8

Bispecific Monoclonal Antibodies for the Targeting of Type I Ribosome-Inactivating Proteins Against Hematological Malignancies

Ferrini, S., Sforzini, S., & Canevari, S. (2003) · Humana Press eBooks · doi:10.1385/1-59259-114-0:177 · Cited by 8

Abstract 3193: Treatment of high Trop-2-expressing triple-negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51

Cardillo, T. M., Mostafa, A. A., Rossi, D. L., Liu, D., Chang, C., Sharkey, R. M., & Goldenberg, D. M. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-3193 · Cited by 8

Bispecific T-cell engager therapy for gastrointestinal cancers

Burton, K. A., Metropulos, A. E., Kamath, S. D., Munshi, H. G., & Principe, D. R. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218417 · Cited by 7

Dual-Variable Domain Immunoglobulin (DVD-Ig™) Technology: A Versatile, Novel Format for the Next Generation of Dual-Targeting Biologics

Tarcsa, E., Fraunhofer, W., Ghayur, T., Salfeld, J. G., & Gu, J. (2011) · Springer eBooks · doi:10.1007/978-3-642-20910-9_10 · Cited by 7

Compact Seahorse‐Shaped T Cell–Activating Antibody for Cancer Therapy

Fujii, H., Tanaka, Y., Nakazawa, H., Sugiyama, A., Manabe, N., Shinoda, A., Shimizu, N., Hattori, T., Hosokawa, K., Sujino, T., et al. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201700031 · Cited by 7

Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release

Aschmoneit, N., Kühl, L., Seifert, O., & Kontermann, R. E. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003616 · Cited by 7

The mosaic puzzle of the therapeutic monoclonal antibodies and antibody fragments - A modular transition from full-length immunoglobulins to antibody mimetics

Khatib, S. E., & Salla, M. (2022) · Leukemia Research Reports · doi:10.1016/j.lrr.2022.100335 · Cited by 8

Bispecific antibodies for multiple myeloma: past, present and future

Ochi, T., Konishi, T., & Takenaka, K. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03766-4 · Cited by 6

Landscape of T-cell engagers in solid tumors

Garcia-Lorenzo, E., Dorta, M., Doger, B., Pedregal, M., & Moreno, V. (2026) · The Oncologist · doi:10.1093/oncolo/oyag129 · Cited by 5

Synthesis of Multiple Bispecific Antibody Formats with Only One Single Enzyme Based on Enhanced Trypsiligase

Voigt, J., Meyer, C., & Bordusa, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063144 · Cited by 5

Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape

Cook, A. L., Sur, S., Dobbyn, L., Watson, E., Cohen, J. D., Ptak, B., Lee, B. S., Paul, S., Hsiue, E. H.-C., Popoli, M., et al. (2025) · eLife · doi:10.7554/elife.95952.3 · Cited by 5

Engineering tandem single-chain Fv as cell surface reporters with enhanced properties of fluorescence detection

Gallo, E., Snyder, A. C., & Jarvik, J. W. (2015) · Protein Engineering Design and Selection · doi:10.1093/protein/gzv016 · Cited by 5

Engineering Antibodies for Cancer Therapy

Goldsmith, L. E., & Robinson, M. K. (2011) · Cell engineering · doi:10.1007/978-94-007-1257-7_10 · Cited by 5

РЕКОМБИНАНТНЫЕ МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА - ОТ ВИЗУАЛИЗАЦИИ ОПУХОЛЕЙ К ИММУНОТЕРАПИИ РАКА. КРИТИЧЕСКИЙ ОБЗОР, "Молекулярная биология"

Mach, J. P. (2017) · Molecular Biology · doi:10.7868/s0026898417060131 · Cited by 5

A comparative study of the bispecific monoclonal antibody, blinatumomab expression in CHO cells and E. coli

Naddafi, F., Shirazi, F. H., Talebkhan, Y., Tabarzad, M., Barkhordari, F., Farahani, Z. A., Bayat, E., Moazzami, R., Mahboudi, F., & Davami, F. (2018) · Preparative Biochemistry & Biotechnology · doi:10.1080/10826068.2018.1525562 · Cited by 5

A bispecific single-chain antibody fusion protein for targeted depletion of autoreactive B cells via unstimulated human T lymphocytes

Zocher, M., & Baeuerle, P. A. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.04.002 · Cited by 4

Blinatumomab in acute lymphoblastic leukemia

Thomas, X., & Lejeune, C. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1143778 · Cited by 4

Engineering antibodies for dual specificity and enhanced potency

Ko, S., & Jung, S. T. (2015) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-014-0575-6 · Cited by 4

Immunotherapy of lymphoma: update and review of the literature

Berdeja, J. G. (2003) · Current Opinion in Oncology · doi:10.1097/00001622-200309000-00003 · Cited by 4

New Recombinant Bi- and Trispecific Antibody Derivatives

Mertens, N., Schoonjans, R., Willems, A. V., Schoonooghe, S., Leœn, J., & Grooten, J. (2001) · Focus on biotechnology · doi:10.1007/0-306-46885-9_12 · Cited by 3

Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?

Doubek, M., & Šmída, M. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1079123 · Cited by 4

IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma

Fei, K., Ni, H., Zhu, M., Kuang, Z., Wu, M., Wu, Z., Wang, F., Zhou, S., Hua, J., Wu, W., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215663 · Cited by 3

Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies

Reed, D. R., & Lum, L. G. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2384086 · Cited by 4

T-cell engaging bispecific antibody therapy

Culp, P. A., Degenhardt, J. D., Dettling, D. E., & May, C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823397-9.00002-8 · Cited by 3

EpCAM-targeted induction of apoptosis

Bremer, E. (2008) · Frontiers in bioscience · doi:10.2741/3062 · Cited by 3

Bispecific antibodies: A promising entrant in cancer immunotherapy

Saini, S., & Kumar, Y. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821972-0.00014-9 · Cited by 3

Bispecific Antibodies and Immune Therapy Targeting

Kiprijanov, S. M. (2011) · Wiley eBooks · doi:10.1002/9783527634057.ch16 · Cited by 3

Entwicklung und Einsatz antiepithelialer Antikörper bei soliden Tumoren

Müller, P. E., & Schlimok, G. (2001) · Der Internist · doi:10.1007/s001080170125 · Cited by 3

Moving Towards the Delivery of Outpatient T-Cell Engaging Therapy for the Management of Multiple Myeloma

Rosenberg, M. C., Scarpetti, L., Morgan, G. J., & Davies, F. E. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.013 · Cited by 2

The path forward for T cell engagers in patients with prostate cancer

Subudhi, S. K., Siddiqui, B. A., Zarrabi, K. K., Kelly, W. K., & Drake, C. G. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013905 · Cited by 2

Bispecific antibodies for cancer therapy: evolution of structural formats and co-targeting strategies from wet-lab to AI-driven in silico modeling

Fan, Z. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218578 · Cited by 2

T Lymphocytes with Modified Specificity in the Therapy of Malignant Diseases

Vdovin, A. S., Быкова, Н. А., & Efimov, G. A. (2017) · Molecular Biology · doi:10.1134/s0026893317060164 · Cited by 2

Comparison of antibody-based immunotherapeutics for malignant hematological disease in an experimental murine model

Frebel, K., Albring, J. C., Wohlgemuth, A., Schwöppe, C., Hailfinger, S., Lenz, G., & Stelljes, M. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011647 · Cited by 2

Selection for Anti-transferrin Receptor Bispecific T-cell Engager in Different Molecular Formats

Fu, M., Guo, Z., Tang, H., Zhu, H., Shen, G., He, Y., & Lei, P. (2020) · Current Medical Science · doi:10.1007/s11596-020-2143-y · Cited by 2

A New Agent in the Strategy to Cure AIDS

Zaia, J. A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.194 · Cited by 2

Monoclonal Antibodies in Pediatric Acute Lymphoblastic Leukemia

Chen, C. I.-U. (2017) · Springer eBooks · doi:10.1007/978-3-319-39708-5_9 · Cited by 2

Les anticorps bispécifiques : une vieille histoire pleine d’avenir… avec les CAR-T !

Riffard, C., & Teillaud, J. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.02.016 · Cited by 2

Bispezifische Antik�rper in der H�matologie und Onkologie

Repp, R., Valerius, T., & Bargou, R. C. (2001) · Der Internist · doi:10.1007/s001080170128 · Cited by 2

Recombinant Monoclonal Antibodies, from Tumor Targeting to Cancer Immunotherapy: A Critical Overview

Mach, J. P. (2017) · Molecular Biology · doi:10.1134/s0026893317060115 · Cited by 2

'Real-time' biomolecular interaction analysis: novel applications and developments

Quinn, J. G. (1999) · Arrow@dit (Dublin Institute of Technology) · Cited by 2

Development of T‐Cell‐Engaging Bispecific Antibody Blinatumomab (Blincyto®) for Treatment of B‐Cell Malignancies

Baeuerle, P. A. (2018) · Wiley eBooks · doi:10.1002/9783527808694.ch5 · Cited by 3

Bispecific antibodies cross-link and redirect CD8 + T cells to kill cytomegalovirus-infected cells

Ali, A. M. A., Balamurugan, A., Ibarrondo, F. J., Nguyen, M., Habibipour, S., Lim, J. M., Hofmann, C., Ng, H. L., & Yang, O. O. (2025) · Science Advances · doi:10.1126/sciadv.ady2092 · Cited by 1

In Vivo Secretion of Bispecific Antibodies Recruiting Lymphocytic Effector Cells

Compte, M., Nuñez‐Prado, N., Sanz, L., & Álvarez‐Vallina, L. (2013) · Antibodies · doi:10.3390/antib2030415 · Cited by 1

Cancer T Cell Immunotherapy with Bispecific Antibodies and Chimeric Antigen Receptors

Lacher, M. D., & Provenzano, M. (2013) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/15748928113088880003 · Cited by 1

Engineering Antibody Molecules

Nezlin, R. S. (1998) · Elsevier eBooks · doi:10.1016/b978-012517970-6/50003-5 · Cited by 1

Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer

Kufer, P., Mack, M., Gruber, R., Lutterbüse, R., Zettl, F., & Riethmüller, G. (1997) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050431 · Cited by 51

Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity

Mack, M., Gruber, R., Schmidt, S., Riethmüller, G., & Kufer, P. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.8.3965 · Cited by 86

Production and characterization of bispecific single-chain antibody fragments

Jonge, J. D., Brissinck, J., Heirman, C., Demanet, C. J., Léo, O., Moser, M., & Thielemans, K. (1995) · Molecular Immunology · doi:10.1016/0161-5890(95)00089-5 · Cited by 34

Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system.

Hayden, M. S., Linsley, P. S., Gayle, M. A., Bajorath, J., Brady, W., Norris, N. A., Fell, H. P., Ledbetter, J. A., & Gilliland, L. K. (1994) · PubMed · Cited by 53

Development and Characterization of a Bispecific Single-Chain Antibody Directed Against T Cells and Ovarian Carcinoma

Kriangkum, J., Xu, B., Gervais, C., Paquette, D., Jacobs, F. A., Martin, L., & Suresh, M. R. (2000) · Hybridoma · doi:10.1089/027245700315770 · Cited by 24